The trademark application was filed by Praimera Biotech AG, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). The application was published for oppositions on October 8, 2024, and still open for oppositions.
The application was filed in German (English was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical drugs
Pharmaceuticals
Biopharmaceuticals for the treatment of cancer
Pharmaceutical preparations for use in oncology
Pharmaceutical preparations for the treatment of cancer
Anti-cancer drugs.
The mark was filed in class 42 with following description of goods:
Research and development in the pharmaceutical and biotechnology fields
Pharmaceutical drug development services
Research relating to biotechnology
Scientific research in the field of pharmacy
Research and development services in the field of antibody technology
Research and development services in the field of antibodies
Research and development in the field of biotechnology